DOSES FOR HORMONE-REFRACTORY PROSTATE CANCER : ADULTS :- INITIALLY 12 TO 14 MG/M2 BSA AS SINGLE IV DOSE ; REPEAT AT 21 DAY INTERVALS.
IT IS DILUTED TO AT LEAST 50 ML IN SODIUM CHLORIDE 0.9% OR GLUCOSE 5% AND INJECTED OVER AT LEAST 3 MINUTES INTO A FREELY-RUNNING INTRAVENOUS INFUSION OF EITHER. SUBSEQUENT DOSES MAY BE ADJUSTED ACCORDING TO THE DEGREE OF MYELOSUPPRESSION PRODUCED. INITIAL DOSAGE MAY NEED TO BE REDUCED TO 12 MG/M2 IN DEBILITATED PATIENTS OR THOSE WHO HAVE HAD PREVIOUS CHEMOTHERAPY
COMBINATION INITIAL THERAPY FOR ANLL IN ADULTS :- 10 - 12 MG/M(SQUARED) DAILY ON DAYS 1-3 GIVEN AS AN I.V. DOSE, AND 100 MG/M (SQUARED) OF CYLARABINE FOR 7 DAYS GIVEN AS A CONTINUOUS 24 HOURS INFUSION ON DAYS 1-7.
ACUTE MYELOID LEUKAEMIA : A DOSE OF 12 MG/M2 DAILY FOR 5 DAYS MAY BE GIVEN TO INDUCE REMISSION; ALTERNATIVELY A SIMILAR DOSE MAY BE GIVEN FOR 3 DAYS WITH CYTARABINE.
CARDIAC EXAMINATIONS ARE RECOMMENDED IN ALL PATIENTS WHO RECEIVE A CUMULATIVE DOSE OF MITOXANTRONE GREATER THAN 160 MG/M2.; LEFT VENTRICULAR EJECTION FRACTION (LVEF) SHOULD BE DETERMINED BEFORE EACH DOSE IN PATIENTS WHO HAVE RECEIVED A CUMULATIVE DOSE IN EXCESS OF 100 MG/M2.
IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, THE RECOMMENDED DOSE IS THE EQUIVALENT OF MITOXANTRONE 12 MG/M2 BY INTRAVENOUS INFUSION OVER 5 TO 15 MINUTES. THIS DOSE MAY BE GIVEN ONCE EVERY 3 MONTHS INITIALLY PROVIDED THAT NEUTROPHIL COUNTS ARE ABOVE 1500 CELLS/MM3 AND THAT LVEF IS GREATER THAN 50%. BLOOD COUNTS SHOULD BE MONITORED BEFORE EACH DOSE.